

## PharmaEngine, Inc.

### Major Decisions made by the Board of Directors in 2023

Date	Major Decisions
Mar. 2, 2023	<ol style="list-style-type: none"> <li>1. Acknowledgement of business report, financial report, and the internal audit report (including ethical management implementation result)</li> <li>2. Acknowledgement of 2022 ESG implementation result, 2023 ESG plan, 2022 ESG assurance fee, 2023 tax report guarantee fee (including review of actual investment of undistributed earnings), review of non-managerial position full-time employee salary information checkup report fee, and the 2022 annual self-evaluation reports of the Remuneration Committee and the Audit Committee</li> <li>3. Acceptance of license-in oncology drug for marketing and sales in Taiwan</li> <li>4. Acceptance of 2022 business report and financial statements</li> <li>5. Acceptance of the examination of the independence, competency qualifications, and fees of Accountants</li> <li>6. Acceptance of establishing “Policy and General Principle of Pre-Authorization of Non-Assurance Services” and the pre-authorization list</li> <li>7. Acceptance of 2022 performance bonus proposal</li> <li>8. Acceptance of 2023 salary adjustment proposal</li> <li>9. Acceptance of percentage of employee compensation and director compensation from 2022 earnings</li> <li>10. Acceptance of 2022 directors’ remuneration package proposal</li> <li>11. Acceptance of 2022 earnings distribution proposal</li> <li>12. Acceptance of effective evaluation of 2022 internal control system and the review of “Internal Control System Declaration”</li> <li>13. Acceptance of the Company’s proposal to dispose shares of Formosa Pharmaceuticals purchased due to the participation of the latter company’s capital raising</li> <li>14. Acceptance of the date, time, and venue of 2023 shareholders’ meeting and the proposals from shareholders with more than 1% shares</li> </ol>
Apr. 27, 2023	<ol style="list-style-type: none"> <li>1. Acknowledgement of business report, financial report, and internal audit report</li> <li>2. Acceptance of the plan to authorize CRO in Taiwan to perform PEP07 later stage Phase 1 solid tumor clinical trial</li> <li>3. Acceptance of first-quarter 2023 financial statements</li> <li>4. Acceptance of the withdrawal and cancellation of restricted shares issued for employee stock awards</li> <li>5. Acceptance of appointment of deputy spokesperson, head of cyber security, and officer of cyber security</li> <li>6. Acceptance of amendments for “Ethical Corporate Management Best Practice Principles”</li> </ol>
Jul. 27, 2023	<ol style="list-style-type: none"> <li>1. Acknowledgement of business report, financial report, and internal audit report</li> <li>2. Acknowledgement of 2022 Sustainability Report and GHG inventory results</li> <li>3. Acknowledgement of report regarding frequently asked questions by investors</li> <li>4. Acceptance of second-quarter 2023 financial statements</li> <li>5. Acceptance of amendments for “Salary Policy, System, Standards and Structure”</li> </ol>

	<ol style="list-style-type: none"> <li>6. Acceptance of amendments for “Supervision and Management of Subsidiaries”</li> <li>7. Acceptance of establishing “Rules Governing Financial and Business Matters between Affiliated Enterprises”</li> <li>8. Acceptance of amendments for “Operational Procedures for Transactions of Derivative Products”</li> <li>9. Acceptance of the withdrawal of restricted shares issued for employee stock awards</li> <li>10. Acceptance of ex-dividend and payout dates for 2022 cash dividend</li> </ol>
Oct. 31, 2023	<ol style="list-style-type: none"> <li>1. Acknowledgement of contract progress, business report, financial report, and the internal audit report</li> <li>2. Acknowledgement of implementation of risk management policy and procedures, intellectual property management and applications, sustainability achievements (including stakeholder communication) and action plan proposal, independent director (in tenure) eligibility criteria evaluation report, 2023 cyber security implementation report, and 2023 board director liability insurance implementation report</li> <li>3. Acceptance of third-quarter 2023 financial statements</li> <li>4. Acceptance of payment authorization for PEP08 achieving drug candidate nomination</li> <li>5. Acceptance of proposal for continuing PEP09 Collaboration and License Agreement</li> <li>6. Acceptance of 2024 business targets and budgets</li> <li>7. Acceptance of 2024 internal audit plan proposal</li> <li>8. Acceptance of amendments for “Internal Control System – Other Management System”</li> </ol>